Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Gwajin Asibiti Ya Cika Maƙasudin Yawan Marasa lafiya don Nazari akan Cutar Alzheimer

Written by edita

Synaptogenix, Inc. a yau ya sanar da cewa ya kammala rajistar maƙasudinsa na marasa lafiya 100 don ci gaba da ci gaba da ci gaba da ci gaba da ci gaba na Cibiyoyin Kiwon Lafiya na Ƙasa (NIH) da ke tallafawa Phase 2b gwajin asibiti na Bryostatin-1 ga marasa lafiya da ke fama da ci gaba da matsananciyar cutar Alzheimer (“AD) ”). Kamfanin yana tsammanin sanar da manyan bayanai daga binciken a cikin kwata na huɗu na 2022.

Synaptogenix kuma ya ba da rahoton cewa Hukumar Kula da Tsaro ta Tsaro mai zaman kanta ("DSMB") da ke sa ido kan gwajin ta tabbatar da rashin duk wani matsala mara kyau da ke da alaƙa da miyagun ƙwayoyi.

Bryostatin-1 ya haifar da ingantacciyar haɓakar fahimi (4.0 SIB psychometric score sama da tushe) ga marasa lafiya da aka riga aka ƙayyade waɗanda suka karɓi Bryostatin-1 in babu Namenda a cikin gwaje-gwajen matukin jirgi na watanni 3 da suka gabata, waɗanda aka buga kwanan nan a cikin takwarorinsu. labarin da aka sake dubawa (JAD, 2022) - yayin da marasa lafiya da aka yi wa Placebo ba su da wani fa'ida mai mahimmanci. An ƙaddamar da maganin Bryostatin-1 don haɗawa da adadin nau'i biyu (N = 14) a cikin watanni na 6 na yanzu, gwajin gwagwarmayar wuribo, wanda aka yi amfani da bazuwar rajista a hankali don ma'auni na asali a cikin jiyya da kuma placebo cohorts. Za a lura da marasa lafiya na tsawon watanni uku bayan duk dakatarwar allurai, idan aka ba da dacewar fa'idar aƙalla kwanaki 30 bayan maganin da aka lura a baya.

"An ƙarfafa mu cewa manyan bayanan layi da aka samu a cikin kwata na 4, 2022, za su nuna irin fa'ida ɗaya ko mafi girma da aka riga aka lura da ita ga marasa lafiya iri ɗaya, waɗanda aka ƙayyade a baya a gwajin gwaji na Mataki na 2a na baya. Rashin duk wani mummunan al'amuran da ke da alaƙa da ƙwayoyi, kamar yadda aka lura tare da wasu ƴan wasu dabarun warkewa da suka kai iyakancewar Hukumar Abinci da Magunguna (FDA) don AD, yakamata ya sauƙaƙe matakanmu na gaba zuwa ga amfanin asibiti. Amfanin aƙalla maki 4.0 SIB, sama da tushe, mai yuwuwa yana da ma'ana a asibiti, don haka suna da damar magance cutar tare da ba da agajin alamun bayyanar, "in ji Daniel Alkon, MD, Shugaban Kamfanin kuma Babban Jami'in Kimiyya. .

Alan Tuchman MD, Babban Jami’in Kamfanin, ya bayyana cewa, “Shaidu suna girma kuma suna ci gaba da tallafawa Bryostatin-1 a matsayin yuwuwar maganin cutar Alzheimer. Muna farin cikin sanar da kammala karatunmu na Phase 2b kuma muna dakon karatun manyan bayanan mu a karshen wannan shekara."

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...